Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

Official title:

Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05720988
• Other study ID #: 21-001115
• Secondary ID: NCI-2021-12912
• Status: Withdrawn
• Phase: Phase 1
• Start date: August 3, 2024
• Est. completion date: August 3, 2026

Study information

• Verified date: January 2023
• Source: Jonsson Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase Ib/II trial tests the safety of tagraxofusp when given with or without azacitidine in patients with acute myeloid leukemia in remission with measurable residual disease who will undergo allogeneic hematopoietic cell transplant. Tagraxofusp is a recombinant protein consisting of IL-3 conjugated to a truncated diptheria toxin. The IL-3 attaches to the cancer cells and the toxic substance kills them. Azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Tagraxofusp and azacitidine may work better to kill cancer cells and eradicate measurable residual disease in patients with acute myeloid leukemia.

Description:

PRIMARY OBJECTIVE: I. To determine the safety and tolerability of tagraxofusp-erzs (tagraxofusp) with or without azacitidine in participants with acute myeloid leukemia (AML) in remission who are planned to undergo allogeneic hematopoietic cell transplantation (alloHCT). SECONDARY OBJECTIVES: I. To estimate the rate of conversion from measurable residual disease (MRD) positive (>= 0.01% by multiparametric flow cytometry [MPFC]) pre-investigational therapy to MRD negative (=< 0.01% by MPFC) after 1 or 2 cycles of investigational therapy. II. To estimate the rate of conversion from MRD positive (>= 0.01% by MPFC) pre-investigational therapy to MRD negative (=< 0.01% by MPFC) post-investigational therapy within 30 days prior to initiation of transplant conditioning regimen and at day +100 following alloHCT. III. To evaluate if adverse effects of this investigational combination leads to delays in alloHCT. IV. To evaluate if this investigational therapy results in liver toxicities after alloHCT such as sinusoidal obstruction syndrome. V. To evaluate relapse rate following alloHCT in participants who receive investigational therapy. VI. To evaluate MRD progression following alloHCT in participants who receive investigational therapy. VII. To evaluate 1-year survival following alloHCT in participants who receive investigational therapy. EXPLORATORY OBJECTIVES: I. To estimate the rate of conversion from MRD positive to MRD negative by means of next generation sequencing. II. To describe the level of CD123 expression on leukemia blasts in the bone marrow specimen at diagnosis and/or time of relapse and the association with achievement of MRD negativity post-investigational therapy. III. To evaluate the number of days to full donor T-cell chimerism following alloHCT. OUTLINE: This is a dose-escalation study of tagraxofusp-erzs . Patients are assigned to 1 of 2 cohorts. COHORT I: Patients receive tagraxofusp-erzs intravenously (IV) once daily (QD) over 15 minutes on days 1-5. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. COHORT II: Patients receive azacitidine subcutaneously (SC) daily on days 1-5 and tagraxofusp-erzs IV QD over 15 minutes on days 8-12. Treatment repeats every 28-42 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 12 months.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 3, 2026
• Est. primary completion date: August 3, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years
• AML in first or second remission, including:
• Complete remission (CR), defined as bone marrow blasts < 5%, absence of circulating blasts, absence of extramedullary disease, absolute neutrophil count (ANC) >= 1,000/uL, platelet count > 100,000/uL
• Complete remission with incomplete hematologic recovery (CRi), defined as all CR criteria except for residual neutropenia (ANC < 1,000/uL) or residual thrombocytopenia (platelet count < 100,000/uL)
• Morphologic leukemia-free state with adequate marrow recovery, defined as bone marrow blasts < 5%, ANC >= 500/uL, and platelet count >= 20,000/uL
• Minimal residual disease positive >= 0.01% based on MPFC
• For participants in first remission, MRD positivity at any point from time of establishing first remission onward while still in first remission
• For participants in second remission, MRD positivity at any point from time of establishing second remission onward while still in second remission
• MRD must be repeated and remain positive if additional treatment is given prior to enrollment
• CD123 positivity on flow cytometry (partial, dim, or bright) from either:
• Conventional flow cytometry on marrow specimen from time of original diagnosis or first relapse
• High-sensitivity multiparametric flow cytometry on marrow specimen from time of MRD positivity
• Eastern Cooperative Oncology Group (ECOG) 0-2
• Serum albumin level >= 3.2 g/dL in the absence of receiving albumin infusion
• Serum total bilirubin =< 1.5 mg/dL, unless considered due to Gilbert's disease or medication effect
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase =< 2.5 times the upper limit of normal, unless considered due to medication effect (eg, azole therapy)
• Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) =< 1.8 mg/dL
• Ability to give full informed consent
• Females of reproductive potential (postmenopausal for less than 24 consecutive months) must have a negative pregnancy test within 1 week of initiating treatment and may not be breastfeeding

Exclusion Criteria:

• MRD negativity < 0.01% at screening
• Intensive AML therapy within the past 14 days, or non-intensive targeted therapy within the past 7 days
• Cord blood as donor source
• Second malignancy that would be expected to limit survival within less than 2 years
• Cardiovascular disease that would result in high risk for toxicity, including:
• Uncontrolled or New York Heart Association (NYHA) class III or VI congestive heart failure
• Recurrent or uncontrolled angina
• Unstable angina, myocardial infarction, or stroke in past 6 months
• Uncontrolled hypertension
• Arrhythmia not controlled by medication
• Left ventricular ejection fraction < 50%
• History of coronary stent placement that requires mandatory continuation of dual antiplatelet therapy
• Uncontrolled intercurrent illness that includes but is not limited to: uncontrolled infection, disseminated intravascular coagulation, psychiatric illness/compliance issues that would limit compliance with study protocol
• Any medical condition that in the opinion of the investigator places the participant at unacceptable risk for toxicity to investigational therapy

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Neoplasm, Residual

Intervention

Drug:
• Azacitidine
Given SC

Biological:
• Tagraxofusp-erzs
Given IV

Locations

Country	Name	City	State
United States	Habtemariam,Bruck	Los Angeles	California
United States	University of California San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Jonsson Comprehensive Cancer Center	Stemline Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	CD123 expression via immunohistochemical stain on leukemia blasts in the bone marrow specimen	CD123 expression, on the original bone marrow specimen at time of diagnosis or time of relapse and the bone marrow specimen at time of MRD negativity, will be described as bright, dim, partial, or negative; and summarized by mean, median, standard deviation, and interquartile range.	at time of diagnosis or relapse and following cycle 1 and cycle 2 (each cycle is 28 days).
Other	T-cell (CD3) chimerism via short tandem repeat assay	Days to achieve full T-cell chimerism following alloHCT will be characterized by Kaplan-Meier methods along with 95% confidence interval.	30, 90, 180, and 365 days after transplant
Primary	Dose-limiting toxicity	Grade >= 3 toxicity using Common Terminology Criteria for Adverse Events version 5.0 or severe persistent hematologic toxicity defined as absolute neutrophil count (ANC) < 500/uL OR platelet count < 10,000/uL in participants that have morphologic leukemia-free state (bone marrow blasts < 5%) are conditions for a dose limiting toxicity.	Up to 42 days
Secondary	Measurable residual disease (MRD)	As measured by the University of Washington multiparametric flow cytometry (MPFC) assay with sensitivity of 0.01%	At the end of cycle 1 and cycle 2 (each cycle is 28 days).
Secondary	MRD	As measured by the University of Washington MPFC assay with sensitivity of 0.01%.	Within 30 days prior to initiation of transplant conditioning regimen and at day 100 after transplant
Secondary	Number of days between investigational regimen day 28 and initiation of transplant conditioning regimen		Between investigational regimen day 28 and initiation of transplant conditioning regimen, through study completion, an average of 1 year.
Secondary	Rate of sinusoidal obstruction syndrome		up to 1 year following investigational therapy
Secondary	Relapse	As defined by International Working Group criteria: the relapse rate and median duration of remission following allogeneic hematopoietic cell transplantation (HCT) will be reported along with an exact 95% confidence interval.	Up to 1 year
Secondary	MRD progression	Defined by presence of leukemia blasts >0.01% at any time after achieving MRD negativity (<0.01%).	Up to 1 year
Secondary	Overall survival	Kaplan-Meier methods will estimate the overall survival at 1 year following allogeneic (allo)HCT. This analysis will be performed using the FAS. The 1-year survival estimate will be reported along with a 95% confidence interval.	1 year after transplant